4.8 Article

Tumor Architecture and Notch Signaling Modulate Drug Response in Basal Cell Carcinoma

期刊

CANCER CELL
卷 33, 期 2, 页码 229-+

出版社

CELL PRESS
DOI: 10.1016/j.ccell.2017.12.015

关键词

-

资金

  1. NIH [R21CA209166, R00AR059796, R01AR065409, R01CA087837, P30CA046592]
  2. UM Department of Dermatology
  3. Biological Sciences Scholars Program
  4. Center for Organogenesis
  5. John S. and Suzanne C. Munn Cancer Fund
  6. Dermatology Foundation Clinical Career Development Award in Dermatologic Surgery

向作者/读者索取更多资源

Hedgehog (Hh) pathway inhibitors such as vismodegib are highly effective for treating basal cell carcinoma (BCC); however, residual tumor cells frequently persist and regenerate the primary tumor upon drug discontinuation. Here, we show that BCCs are organized into two molecularly and functionally distinct compartments. Whereas interior Hh(+)/Notch(+) suprabasal cells undergo apoptosis in response to vismodegib, peripheral Hh(+++)/Notch(-) basal cells survive throughout treatment. Inhibiting Notch specifically promotes tumor persistence without causing drug resistance, while activating Notch is sufficient to regress already established lesions. Altogether, these findings suggest that the three-dimensional architecture of BCCs establishes a natural hierarchy of drug response in the tumor and that this hierarchy can be overcome, for better or worse, by modulating Notch.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据